Amgen has been handed an FDA warning letter over a video promoting its cancer drug Vectibix, but the company said the issues ...

Eli Lilly is consolidating its U.S. and international commercial divisions into a unified department, tapping current U.S.

GSK's chief executive Luke Miels has committed to a transparent communication strategy after telling analysts during its Q3 ...

Strategic consulting firm Blue Matter is boosting its communications digs with the acquisition of global healthcare ...

Biogen’s third quarter revenues beat out Wall Street estimates in what CEO Chris Viehbacher called “one of these quarters where the numbers almost just speak for themselves.” | Biogen CEO Chris ...

With regulatory go-aheads now locked down in the U.S. and Japan, China is the next priority for GSK. The company’s president of global product strategy, Nina Mojas, noted on a conference call that the ...

Eli Lilly has jumped up a ranking of the corporate reputations of diabetes drugmakers, putting it hot on the heels of Novo. | Eli Lilly has jumped up a ranking of the corporate reputations of diabetes ...

Vanda Pharmaceutical’s Nereus may soon break out of its motion sickness niche to become a treatment option for the burgeoning ...

Things have been relatively quiet on the layoff front for the company in 2026, although it was widely reported in June that ...

Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...

A U.S. judge has ruled Eli Lilly can keep making marketing claims challenged by Novo pending a ruling on a court case brought ...

As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...